	US 12,337,030 B2
	Viral vector
Vincenzo Cerullo, Helsinki (FI); Cristian Capasso, Milan (IT); Sara Feola, Helsinki (FI); and Siri Tahtinen, Helsinki (FI)
Assigned to Valo Therapeutics Oy, Helsinki (FI)
Appl. No. 17/614,064
Filed by Valo Therapeutics Oy, Helsinki (FI)
PCT Filed May 21, 2020, PCT No. PCT/EP2020/064215 § 371(c)(1), (2) Date Nov. 24, 2021, PCT Pub. No. WO2020/239609, PCT Pub. Date Dec. 3, 2020.
Claims priority of application No. 1907413 (GB), filed on May 24, 2019.
Prior Publication US 2022/0288184 A1, Sep. 15, 2022
Int. Cl. A61K 39/12 (2006.01); A61K 39/00 (2006.01); A61K 47/00 (2006.01); A61P 35/00 (2006.01); C12N 7/00 (2006.01); C12N 15/00 (2006.01)

CPC A61K 39/12 (2013.01) [A61K 39/0011 (2013.01); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001192 (2018.08); A61K 47/00 (2013.01); A61P 35/00 (2018.01); A61K 2039/5256 (2013.01); A61K 2039/55544 (2013.01); A61K 2039/572 (2013.01)]

20 Claims

1. A viral vector having attached to its viral capsid or envelope, polypeptides that are not genetically encoded by said viral vector but are attached to the capsid or envelope covalently or non-covalently, wherein:

i) at least one of said polypeptides comprises an antigen from, or of, a pathogen that a subject has been prior immunised against; and

ii) at least one other of said polypeptides is a tumor or cancer specific polypeptide and so stimulates an anti-tumor or anti-cancer immune response in a subject exposed to said vector.